In addition, Tanabe Pharma has entered into an exclusive sublicensing agreement with Nippon Shinyaku Co., Ltd., for the commercialization of ZYNLONTA in Japan.

Recently, encouraging results from the Phase 1/2 MT-2111-A-101 bridging study evaluating ZYNLONTA monotherapy in Japanese patients with relapsed or refractory DLBCL were presented at the Japanese Society of Hematology meeting. In the Phase 2 portion of the study in Japan, ZYNLONTA demonstrated an overall response rate of 58.1%, including a complete response rate of 41.9%, with median duration of response not reached at a median follow-up of 15.21 months. The findings were consistent with the pivotal LOTIS-2 global study, with no new safety concerns identified. Based on these results, Tanabe Pharma filed the marketing authorization application for ZYNLONTA in Japan.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.